



NATIONAL CANCER INSTITUTE

Grant Number: 5P30CA006927-54
FAIN: P30CA006927

Principal Investigator(s):
RICHARD I FISHER, MD

Project Title: Comprehensive Cancer Center Program at Fox Chase

Maria Gill
Director, Office of Sponsored Research
RESEARCH INST OF FOX CHASE CAN CTR
333 Cottman Avenue
Philadelphia, PA 191112434

Award e-mailed to: awardnotices@fccc.edu

Period Of Performance:

Budget Period: 08/01/2019 – 07/31/2020

Project Period: 07/01/1997 – 07/31/2021

Dear Business Official:

The National Institutes of Health hereby awards a grant in the amount of \$2,905,436 (see "Award Calculation" in Section I and "Terms and Conditions" in Section III) to RESEARCH INST OF FOX CHASE CAN CTR in support of the above referenced project. This award is pursuant to the authority of 42 USC 241 42 CFR 52 and is subject to the requirements of this statute and regulation and of other referenced, incorporated or attached terms and conditions.

Acceptance of this award including the "Terms and Conditions" is acknowledged by the grantee when funds are drawn down or otherwise obtained from the grant payment system.

Each publication, press release, or other document about research supported by an NIH award must include an acknowledgment of NIH award support and a disclaimer such as "Research reported in this publication was supported by the National Cancer Institute of the National Institutes of Health under Award Number P30CA006927. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health." Prior to issuing a press release concerning the outcome of this research, please notify the NIH awarding IC in advance to allow for coordination.

Award recipients must promote objectivity in research by establishing standards that provide a reasonable expectation that the design, conduct and reporting of research funded under NIH awards will be free from bias resulting from an Investigator's Financial Conflict of Interest (FCOI), in accordance with the 2011 revised regulation at 42 CFR Part 50 Subpart F. The Institution shall submit all FCOI reports to the NIH through the eRA Commons FCOI Module. The regulation does not apply to Phase I Small Business Innovative Research (SBIR) and Small Business Technology Transfer (STTR) awards. Consult the NIH website <http://grants.nih.gov/grants/policy/coi/> for a link to the regulation and additional important information.

If you have any questions about this award, please contact the individual(s) referenced in Section IV.

Sincerely yours,

Dawn M. Mitchum
Grants Management Officer
NATIONAL CANCER INSTITUTE

Additional information follows

SECTION I – AWARD DATA – 5P30CA006927-54**Award Calculation (U.S. Dollars)**

Federal Direct Costs	\$1,575,000
Federal F&A Costs	\$1,330,436
Approved Budget	\$2,905,436
Total Amount of Federal Funds Obligated (Federal Share)	\$2,905,436
TOTAL FEDERAL AWARD AMOUNT	\$2,905,436

AMOUNT OF THIS ACTION (FEDERAL SHARE)	\$2,905,436
--	--------------------

SUMMARY TOTALS FOR ALL YEARS		
YR	THIS AWARD	CUMULATIVE TOTALS
54	\$2,905,436	\$2,905,436
55	FUTURE COSTS, RECOMMENDED COSTS	

Recommended future year total cost support, subject to the availability of funds and satisfactory progress of the project

Fiscal Information:

CFDA Name: Cancer Centers Support Grants
CFDA Number: 93.397
EIN: 1236296135A1
Document Number: PCA006927L
PMS Account Type: P (Subaccount)
Fiscal Year: 2019

IC	CAN	2019	2020
CA	8423165	\$2,905,436	FUTURE COSTS, RECOMMENDED COSTS

Recommended future year total cost support, subject to the availability of funds and satisfactory progress of the project

NIH Administrative Data:

PCC: 1XMD / **OC:** 414E / **Released:** MITCHUMD 08/14/2019
Award Processed: 08/15/2019 12:07:13 AM

SECTION II – PAYMENT/HOTLINE INFORMATION – 5P30CA006927-54

For payment and HHS Office of Inspector General Hotline information, see the NIH Home Page at <http://grants.nih.gov/grants/policy/awardconditions.htm>

SECTION III – TERMS AND CONDITIONS – 5P30CA006927-54

This award is based on the application submitted to, and as approved by, NIH on the above-titled project and is subject to the terms and conditions incorporated either directly or by reference in the following:

- The grant program legislation and program regulation cited in this Notice of Award.
- Conditions on activities and expenditure of funds in other statutory requirements, such as those included in appropriations acts.
- 45 CFR Part 75.
- National Policy Requirements and all other requirements described in the NIH Grants Policy Statement, including addenda in effect as of the beginning date of the budget period.
- Federal Award Performance Goals: As required by the periodic report in the RPPR or in the final progress report when applicable.
- This award notice, INCLUDING THE TERMS AND CONDITIONS CITED BELOW.

(See NIH Home Page at <http://grants.nih.gov/grants/policy/awardconditions.htm> for certain references cited above.)

Obtained by Rise for Animals. Uploaded 08/19/2020

Research and Development (R&D): All awards issued by the National Institutes of Health (NIH) meet the definition of "Research and Development" at 45 CFR Part§ 75.2. As such, auditees should identify NIH awards as part of the R&D cluster on the Schedule of Expenditures of Federal Awards (SEFA). The auditor should test NIH awards for compliance as instructed in Part V, Clusters of Programs. NIH recognizes that some awards may have another classification for purposes of indirect costs. The auditor is not required to report the disconnect (i.e., the award is classified as R&D for Federal Audit Requirement purposes but non-research for indirect cost rate purposes), unless the auditee is charging indirect costs at a rate other than the rate(s) specified in the award document(s).

An unobligated balance may be carried over into the next budget period without Grants Management Officer prior approval.

This grant is excluded from Streamlined Noncompeting Award Procedures (SNAP).

This award is subject to the requirements of 2 CFR Part 25 for institutions to receive a Dun & Bradstreet Universal Numbering System (DUNS) number and maintain an active registration in the System for Award Management (SAM). Should a consortium/subaward be issued under this award, a DUNS requirement must be included. See <http://grants.nih.gov/grants/policy/awardconditions.htm> for the full NIH award term implementing this requirement and other additional information.

This award has been assigned the Federal Award Identification Number (FAIN) P30CA006927. Recipients must document the assigned FAIN on each consortium/subaward issued under this award.

This award is not subject to the Transparency Act subaward and executive compensation reporting requirement of 2 CFR Part 170.

In accordance with P.L. 110-161, compliance with the NIH Public Access Policy is now mandatory. For more information, see NOT-OD-08-033 and the Public Access website: <http://publicaccess.nih.gov/>.

This award provides support for one or more clinical trials. By law (Title VIII, Section 801 of [Public Law 110-85](#)), the "responsible party" must register "applicable clinical trials" on the [ClinicalTrials.gov Protocol Registration System Information Website](#). NIH encourages registration of all trials whether required under the law or not. For more information, see http://grants.nih.gov/ClinicalTrials_fdaaa/

In accordance with the regulatory requirements provided at 45 CFR 75.113 and Appendix XII to 45 CFR Part 75, recipients that have currently active Federal grants, cooperative agreements, and procurement contracts with cumulative total value greater than \$10,000,000 must report and maintain information in the System for Award Management (SAM) about civil, criminal, and administrative proceedings in connection with the award or performance of a Federal award that reached final disposition within the most recent five-year period. The recipient must also make semiannual disclosures regarding such proceedings. Proceedings information will be made publicly available in the designated integrity and performance system (currently the Federal Awardee Performance and Integrity Information System (FAPIIS)). Full reporting requirements and procedures are found in Appendix XII to 45 CFR Part 75. This term does not apply to NIH fellowships.

Treatment of Program Income:
Additional Costs

SECTION IV – CA Special Terms and Conditions – 5P30CA006927-54

Clinical Trial Indicator: Yes

This award supports one or more NIH-defined Clinical Trials. See the NIH Grants Policy Statement Section 1.2 for NIH definition of Clinical Trial.

Obtained by Rise for Animals. Uploaded 08/19/2020

REQUIREMENT: The awardee is required to adhere to the [Cancer Center Support \(CCSG\) Guidelines](#).

REQUIREMENT: The requirements contained in the document, "Intellectual Property Option to Collaborator," are incorporated by reference as a condition of this award. The "Intellectual Property Option to Collaborator" document may be accessed at http://ctep.cancer.gov/industryCollaborations2/docs/Intellectual_Property_Option_to_Collaborator_s.doc or may be obtained from the Regulatory Affairs Branch, Cancer Therapy Evaluation Program, Division of Cancer Treatment and Diagnosis, NCI at (240) 276-6580.

REQUIREMENT: The Fox Chase Cancer Center is required to report all interventional trials supported in whole or in part by this award into the Clinical Trials Reporting Program (CTRP) database. This requirement includes externally peer-reviewed, institutional and industrial trials that utilize the supporting infrastructure of the NCI funded Cancer Center.

REQUIREMENT: The awardee is required to follow the data and safety monitoring plan dated 5/8/18 and may not implement any changes in the plan without the written prior approval of the National Cancer Institute.

REQUIREMENT: The awardee is required to follow the Data Sharing plan included in the competing application and may not implement any changes in the plan without the written prior approval of the National Cancer Institute.

REQUIREMENT: The awardee is required to follow the Model Sharing plan included in the competing application and may not implement any changes in the plan without the written prior approval of the National Cancer Institute.

INFORMATION: The Fox Chase Cancer Center has been approved as an NCI-designated Comprehensive Cancer Center in accordance with PAR-17-095. The NCI has registered, as a badge, the term "NCI-designated Comprehensive Cancer Center." An approved Center may identify itself accordingly by reflecting the official NCI-designated Comprehensive Cancer Center badge on its stationery and publications.

INFORMATION: This project involves hazardous or potentially hazardous agents. Attention is called to the Health and Safety Regulations and Guidelines (Section 4.1.12) of the [NIH Grants Policy Statement](#).

INFORMATION: This award involves Human Subjects Research. See "Assurance Requirements and Institutional Review Boards" under Part II, Subpart A, Human Subjects, in the [NIH Grants Policy Statement](#), for specific requirements and grantee responsibilities related to the protection of human subjects, which are applicable to and are a term and condition of this award.

This award reflects the National Cancer Institute's acceptance of the certification that all key personnel have completed education on the protection of human subjects, in accordance the [NIH Grants Policy Statement](#), "Education in the Protection of Human Research Subjects."

Any individual involved in the design and conduct of the study that is not included in the certification must satisfy this requirement prior to participating in the project. Failure to comply can result in the suspension and/or termination of this award, withholding of support of the continuation award, audit disallowances, and/or other appropriate action.

INFORMATION: In accordance with the Office of Policy for Extramural Research (OPERA) approval letter dated 6/25/19; this award adjusts the indirect costs rate (F&A) from 83% to 87% effective 8/1/19. No action by the awardee is required.

STAFF CONTACTS

The Grants Management Specialist is responsible for the negotiation, award and administration of this project and for interpretation of Grants Administration policies and provisions. The Program Official is responsible for the scientific, programmatic and technical aspects of this project. These individuals work together in overall project administration. Prior approval requests (signed by an

Obtained by Rise for Animals. Uploaded 08/19/2020

Authorized Organizational Representative) should be submitted in writing to the Grants Management Specialist. Requests may be made via e-mail.

Grants Management Specialist: Candace M Cofie
Email: candace.cofie@nih.gov **Phone:** (240) 276-5721

Program Official: Hasnaa Shafik
Email: shafikh@mail.nih.gov **Phone:** 240-276-5600 **Fax:** 240-276-5625

SPREADSHEET SUMMARY
GRANT NUMBER: 5P30CA006927-54

INSTITUTION: RESEARCH INST OF FOX CHASE CAN CTR

Budget	Year 54	Year 55
TOTAL FEDERAL DC	\$1,575,000	FUTURE COSTS
TOTAL FEDERAL F&A	\$1,330,436	
TOTAL COST	\$2,905,436	

Facilities and Administrative Costs	Year 54	Year 55
F&A Cost Rate 1	87%	FUTURE COSTS
F&A Cost Base 1	\$1,529,237	
F&A Costs 1	\$1,330,436	

A. COMPONENT COVER PAGE

Project Title: Shared Resource: Laboratory Animal Facility

Component Project Lead Information:

Veeder, Christin

B. COMPONENT ACCOMPLISHMENTS**B.1 WHAT ARE THE MAJOR GOALS OF THE PROJECT?**

The Laboratory Animal Facility (LAF) is critical to the laboratory animal research needs of Fox Chase Cancer Center (FCCC). The LAF provides a shared resource that allows the creation and use of translational animal models for all five Research Programs in a cost effective and collaborative manner. The specific aims of the Laboratory Animal Facility are to:

Aim 1. Provide exemplary animal care for multiple species of animals for FCCC members and to ensure their needs are being met as defined in the Guide for the Care and Use of Laboratory Animals (8th ed.). This includes various species such as mice, rats and zebrafish.

Aim 2. Assure the optimal health of all research animals housed at FCCC so that there is no interference or interruption of Research Programs utilizing animals as part of their research endeavors.

This will involve an assured supply of healthy transgenic, conventional immunocompetent and immunocompromised animals. To accomplish this, the Facility has a rigorous surveillance program for detection of organisms of veterinary importance. This aim employs the use of a robust and rigorous assay program consisting of the use of Multiplexed Fluorometric ImmunoAssay (MFIA), polymerase chain reaction assays (PCR), microbiology and histopathology.

Aim 3. Provide an array of in vivo technical support and services for all FCCC members and staff upon request.

The Laboratory Animal Health services offered by the LAF, in conjunction with the Transgenic Mouse Facility, rederives mice by both germ-free cesarean and embryo transfer to restrict the possibility of introducing pathogens into the Facility. This results in a Facility that reduces the risk of importing unwanted infectious agents and genetic contaminants into the FCCC animal care and use program up front before research is initiated. The Laboratory Animal Facility offers technical services to investigators including surgery, tumor implantation, injections, gavage and blood collection. The Genetic Monitoring service provides breeding colony management and, in conjunction with the Genomics Facility, genotyping data for rodent breeding colonies housed in the LAF.

Aim 4. Provide scientific and technical support and advice through consultation and professional dialogue with FCCC members.

- a) LAF staff have specific expertise, skills, knowledge and experience in developing and adapting various translational models in immunology, oncology, and infectious diseases. They provide a valuable resource to FCCC to ensure that animal models and animal use has fidelity as a translational model in research.
- b) Zebrafish staff (Rhodes) offer specific expertise in the use of zebrafish in research conducted at FCCC.
- c) LAF staff manages and operates a high quality breeding colony for C.B17 SCID and NSG mice for use in the Patient Derived Xenograft (PDX) and bone marrow transplant studies. These colonies total approximately 200 cages.

B.1.a Have the major goals changed since the initial competing award or previous report?

No

B.2 WHAT WAS ACCOMPLISHED UNDER THESE GOALS?

File uploaded: B2_LAF_Accomplishments.pdf

B.3 COMPETITIVE REVISIONS/ADMINISTRATIVE SUPPLEMENTS

Not Applicable

B.4 WHAT OPPORTUNITIES FOR TRAINING AND PROFESSIONAL DEVELOPMENT HAS THE PROJECT PROVIDED?

NOTHING TO REPORT

B.5 HOW HAVE THE RESULTS BEEN DISSEMINATED TO COMMUNITIES OF INTEREST?

NOTHING TO REPORT

B.6 WHAT DO YOU PLAN TO DO DURING THE NEXT REPORTING PERIOD TO ACCOMPLISH THE GOALS?

The LAF has plans to expand the use of gnotobiotic isolators. This process will include beginning the rederivation process to eliminate *Helicobacter* spp. Mouse Norovirus (MNV), and *Corynebacterium* bovis. This procedure will help the Facility to achieve the long-term goal of a specific pathogen free status. The LAF plans to purchase five (5) additional gnotobiotic isolators to be used as part of the PDX bone marrow transplant studies. The institution is budgeting funds in 2019 to replace the ventilation motors on the high density ventilated caging units in the LAF.

The LAF staff will continue to meet the needs of Cancer Center members who require the use of mice and zebrafish for their approved studies.

B2. Accomplishments – Laboratory Animal Facility

Changes to Roles or Functions of Resource Leadership

In April, 2018 the Facility Director and Attending Veterinarian, Dr. Steven Kuhlman, retired. In the interim, the LAF has contracted with Beverly Jan Gnad, D.V.M., A.C.L.A.M. from Temple University to serve as the interim Attending Veterinarian. A new Facility Director and Attending Veterinarian, Christin L. Veeder, MLAS, VMD, DACLAM joined FCCC and began work in November 2018. Dr. Veeder has worked in the field of laboratory animal research since 1998 and has expertise in behavioral management. Dr. Veeder has assumed all responsibilities to oversee the facility including the sentinel surveillance program. She is also a member the Institutional Animal Care and Use Committee.

Major Changes in the Resource's Scientific and/or Technical Capabilities

The Laboratory Animal Facility (LAF) continues to send sentinel samples to IDEXX for comprehensive health screening test which include additional murine pathogens, murine parasites and PCR screening for *Corynebacterium bovis*. The LAF, under the leadership of Dr. Christin Veeder, is evaluating the use of exhaust air dust and environmental monitoring as a component of the health surveillance program. The LAF is also working with the vendors and animal care staff to establish an effective sanitation/decontamination program concerning animal pathogens.

C. COMPONENT PRODUCTS**C.1 PUBLICATIONS**

Not Applicable

C.2 WEBSITE(S) OR OTHER INTERNET SITE(S)

Not Applicable

C.3 TECHNOLOGIES OR TECHNIQUES

NOTHING TO REPORT

C.4 INVENTIONS, PATENT APPLICATIONS, AND/OR LICENSES

Not Applicable

C.5 OTHER PRODUCTS AND RESOURCE SHARING

Nothing to report

D. COMPONENT PARTICIPANTS

Not Applicable

E. COMPONENT IMPACT

E.1 WHAT IS THE IMPACT ON THE DEVELOPMENT OF HUMAN RESOURCES?

Not Applicable

E.2 WHAT IS THE IMPACT ON PHYSICAL, INSTITUTIONAL, OR INFORMATION RESOURCES THAT FORM INFRASTRUCTURE?

Not Applicable

E.3 WHAT IS THE IMPACT ON TECHNOLOGY TRANSFER?

NOTHING TO REPORT

E.4 WHAT DOLLAR AMOUNT OF THE AWARD'S BUDGET IS BEING SPENT IN FOREIGN COUNTRY(IES)?

Not Applicable

F. COMPONENT CHANGES**F.1 CHANGES IN APPROACH AND REASONS FOR CHANGE**

Not Applicable

F.2 ACTUAL OR ANTICIPATED CHALLENGES OR DELAYS AND ACTIONS OR PLANS TO RESOLVE THEM

NOTHING TO REPORT

F.3 SIGNIFICANT CHANGES TO HUMAN SUBJECTS, VERTEBRATE ANIMALS, BIOHAZARDS, AND/OR SELECT AGENTS**F.3.a Human Subjects**

No Change

F.3.b Vertebrate Animals

No Change

F.3.c Biohazards

No Change

F.3.d Select Agents

No Change

G. COMPONENT SPECIAL REPORTING REQUIREMENTS

G.1 SPECIAL NOTICE OF AWARD TERMS AND FUNDING OPPORTUNITIES ANNOUNCEMENT REPORTING REQUIREMENTS

Not Applicable

G.2 RESPONSIBLE CONDUCT OF RESEARCH

Not Applicable

G.3 MENTOR'S REPORT OR SPONSOR COMMENTS

Not Applicable

G.4 HUMAN SUBJECTS**G.4.a Does the project involve human subjects?**

No

G.4.b Inclusion Enrollment Data

Not Applicable

G.4.c ClinicalTrials.gov

Not Applicable

G.5 HUMAN SUBJECTS EDUCATION REQUIREMENT

Not Applicable

G.6 HUMAN EMBRYONIC STEM CELLS (HESCS)

Does this project involve human embryonic stem cells (only hESC lines listed as approved in the NIH Registry may be used in NIH funded research)?

No

G.7 VERTEBRATE ANIMALS

Not Applicable

G.8 PROJECT/PERFORMANCE SITES

Not Applicable

G.9 FOREIGN COMPONENT

Not Applicable

G.10 ESTIMATED UNOBLIGATED BALANCE

Not Applicable

G.11 PROGRAM INCOME

Not Applicable

G.12 F&A COSTS

Not Applicable

--

RPPR - Core-6957

RESEARCH & RELATED BUDGET - SECTION A & B FINAL

ORGANIZATIONAL DUNS*: 064367329

Budget Type*: ● Project ○ Subaward/Consortium

Enter name of Organization: RESEARCH INST OF FOX CHASE CAN CTR

Start Date*: 08-01-2019

End Date*: 07-31-2020

A. Senior/Key Person												
Prefix	First Name*	Middle Name	Last Name*	Suffix	Project Role*	Base Salary (\$)	Calendar Months	Academic Months	Summer Months	Requested Salary (\$)*	Fringe Benefits (\$)*	Funds Requested (\$)*
1. Dr	Christin		Veeder		Core Lead	CAL. MONTHS: INST. BASE SALARY				16,872.00	1,940.00	18,812.00
Total Funds Requested for all Senior Key Persons in the attached file												
Additional Senior Key Persons: File Name:											Total Senior/Key Person	18,812.00

B. Other Personnel							
Number of Personnel*	Project Role*	Calendar Months	Academic Months	Summer Months	Requested Salary (\$)*	Fringe Benefits*	Funds Requested (\$)*
	Post Doctoral Associates						
	Graduate Students						
	Undergraduate Students						
	Secretarial/Clerical						
5	Manager/Other Facility Personnel	58.8			10,639.00	2,798.00	13,437.00
5	Total Number Other Personnel					Total Other Personnel	13,437.00
						Total Salary, Wages and Fringe Benefits (A+B)	32,249.00

RESEARCH & RELATED Budget (A-B) (Funds Requested)